PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34514006-9	2021	To clarify the role of COX-2 in ADSC-CM-induced KFB apoptosis, a specific COX-2 inhibitor, celecoxib, was applied to KFBs cultured in ADSC-CM.	Celecoxib	91-100	cytochrome c oxidase II, mitochondrial	Mus musculus	74-79	
33793216-1	2021	A ligand-based approach involving systematic modifications of a trisubstituted pyrazoline scaffold derived from the COX2 inhibitor, celecoxib, was used to develop novel PDE5 inhibitors.	Celecoxib	132-141	cytochrome c oxidase II, mitochondrial	Mus musculus	116-120	
35526488-8	2022	ACOX1 specific inhibitor mixed in the liquid diets restored both the WY-14,643-suppressed liver TG and PGE2, but COX-2 specific inhibitor celecoxib mixed in the liquid diets reversed the WY-14,643-suppressed liver TG but not liver PGE2 contents.	Celecoxib	138-147	cytochrome c oxidase II, mitochondrial	Mus musculus	113-118	
34372885-6	2021	RESULTS: Series 1: BI 1029539 or celecoxib reduced LPS-induced lung injury, with reduction in neutrophil influx, protein content, TNF-alpha, IL-1beta and PGE2 levels in bronchoalveolar lavage (BAL), myeloperoxidase activity, expression of mPGES-1, cyclooxygenase (COX)-2 and intracellular adhesion molecule in lung tissue compared with vehicle-treated mice.	Celecoxib	33-42	cytochrome c oxidase II, mitochondrial	Mus musculus	248-270	
35128814-2	2022	One is I-IR799-CXB which I-IR799 was conjugated to COX-2 specific inhibitor, celecoxib, and another is I-IR799-IMC , where the non-selective COX inhibitor, indomethacin, was used.	Celecoxib	77-86	cytochrome c oxidase II, mitochondrial	Mus musculus	51-56	
33593853-10	2021	Systemic administration of the COX2 inhibitor celecoxib suppressed both PGE2-induced heat hyperalgesia and Pdha1 phosphorylation in DRG of males but not females, suggesting that prostaglandin synthesis within the DRG mediates the phosphorylation of Pdha1 in response to hindpaw insult.SIGNIFICANCE STATEMENTThere has been extensive investigation of mitochondrial dysfunction as a causative factor in neuropathic pain disorders.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Mus musculus	31-35	
33837224-7	2021	Celecoxib, a selective COX-2 inhibitor, limited upregulation of Ptgs2 in BECs.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
35456720-11	2022	Along with the COX-2 inhibition, celecoxib might have an anti-psoriasis effect by other independent mechanisms.	Celecoxib	33-42	cytochrome c oxidase II, mitochondrial	Mus musculus	15-20	
32365663-6	2020	Surprisingly, celecoxib, a known COX-2 inhibitor, prevented the emergence of drug-induced MDR in murine and canine lymphoma cell lines.	Celecoxib	14-23	cytochrome c oxidase II, mitochondrial	Mus musculus	33-38	
33403674-12	2021	CONCLUSIONS: Selective COX-2 inhibitor Celecoxib reduced osteoclastogenic signaling and activity that dampened bone resorption in LPS-induced apical periodontitis in mice, with greater efficacy than non-selective inhibitor Indomethacin.	Celecoxib	39-48	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
32266025-0	2020	Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
32266025-1	2020	The aim of the present study was to evaluate the effects of the selective cyclooxygenase (COX)-2 inhibitor celecoxib on the development of uterine adenomyosis in mice.	Celecoxib	107-116	cytochrome c oxidase II, mitochondrial	Mus musculus	74-96	
32266025-13	2020	Taken together, the results of the present study support the potential use of celecoxib, a selective COX-2 inhibitor, for the treatment of adenomyosis.	Celecoxib	78-87	cytochrome c oxidase II, mitochondrial	Mus musculus	101-106	
30875493-4	2019	In this study, the effects of celecoxib, a selective COX-2 inhibitor, on AS and the COX-2 and 5-LO pathways were investigated in vivo and in vitro.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Mus musculus	53-58	
32266177-5	2020	The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration.	Celecoxib	164-173	cytochrome c oxidase II, mitochondrial	Mus musculus	18-23	
32642723-4	2020	As COX-2 modulates PD-L1 expression in cancer cells, we tested the hypothesis that the COX-2 inhibitor celecoxib potentiates anti-PD-1 antibody treatment via the downregulation of PD-L1.	Celecoxib	103-112	cytochrome c oxidase II, mitochondrial	Mus musculus	3-8	
32642723-4	2020	As COX-2 modulates PD-L1 expression in cancer cells, we tested the hypothesis that the COX-2 inhibitor celecoxib potentiates anti-PD-1 antibody treatment via the downregulation of PD-L1.	Celecoxib	103-112	cytochrome c oxidase II, mitochondrial	Mus musculus	87-92	
31534549-14	2019	Finally, we demonstrated that combinatorial inhibition of COX-2 and DNMT using Celecoxib and Decitabine synergistically inhibited GC growth in vitro and in vivo.	Celecoxib	79-88	cytochrome c oxidase II, mitochondrial	Mus musculus	58-63	
31170675-1	2019	Cilostazol exerts potent anti-inflammatory effects and celecoxib, a COX-2 specific inhibitor, improves the unsatisfactory profile of NSAIDs.	Celecoxib	55-64	cytochrome c oxidase II, mitochondrial	Mus musculus	68-73	
30875493-9	2019	Celecoxib also decreased the protein and mRNA expression of COX-2 but increased the expression of 5-LO and LTC4S in both ApoE-/- mouse aortic tissues and LPS-stimulated RAW264.7 macrophages.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	60-65	
30875493-10	2019	CONCLUSION: The COX-2-selective inhibitor celecoxib can aggravate atherogenesis, an effect that may be related to upregulation of LTs via a 5-LO pathway shunt.	Celecoxib	42-51	cytochrome c oxidase II, mitochondrial	Mus musculus	16-21	
30021726-4	2018	ASA and the COX-2 inhibitor celecoxib did not affect melanoma cell viability, but significantly reduced colony formation, cell motility, and pigmentation (melanin production) in vitro at concentrations of 1 mmol/L and 20 mumol/L, respectively.	Celecoxib	28-37	cytochrome c oxidase II, mitochondrial	Mus musculus	12-17	
30819896-5	2019	Ectopic expression of prolactin receptor in mouse cancer cells enhances micrometastasis, while treatment with the COX-2 inhibitor celecoxib abrogates prolactin secretion by fibroblasts and reduces tumor initiation.	Celecoxib	130-139	cytochrome c oxidase II, mitochondrial	Mus musculus	114-119	
31587584-9	2019	Further, COX-2 inhibitor, celecoxib, was effective in relieving swelling and inflammation in Cr-allergic mice concordant with suppression of IFN-gamma production by CD8+ T cells and T cell accumulation in the lymph nodes.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Mus musculus	9-14	
30738643-8	2019	CONCLUSION: Cox-2 inhibition led to an enhanced trans-differentiation of WJ-MSCs into ECs that, when transplanted, accelerated the skin regeneration by engraftment and neo-vascularization at the wound bed, suggesting a plausible new therapeutic role of celecoxib.	Celecoxib	253-262	cytochrome c oxidase II, mitochondrial	Mus musculus	12-17	
29371019-1	2018	Celecoxib (CLX) is a selective COX-2 inhibitor with anticancer potential in a COX-2 dependent and independent manner.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36	
29723037-4	2018	Based on these findings, we sought to determine the effects of other potent p38 activators, including the cyclooxygenase (COX)-2 inhibitor celecoxib.	Celecoxib	139-148	cytochrome c oxidase II, mitochondrial	Mus musculus	106-128	
29923556-4	2018	Herein, celecoxib (CLX) and Brefeldin A (BFA) were encapsulated into the biocompatible polymer PLGA-PEG to form nanoparticles that act on the Golgi apparatus to treat metastatic breast cancer; CLX is a specific COX-2 inhibitor which accumulates in the Golgi apparatus, and BFA is a protein transport inhibitor fusing the Golgi apparatus into endoplasmic reticulum.	Celecoxib	8-17	cytochrome c oxidase II, mitochondrial	Mus musculus	211-216	
29923556-4	2018	Herein, celecoxib (CLX) and Brefeldin A (BFA) were encapsulated into the biocompatible polymer PLGA-PEG to form nanoparticles that act on the Golgi apparatus to treat metastatic breast cancer; CLX is a specific COX-2 inhibitor which accumulates in the Golgi apparatus, and BFA is a protein transport inhibitor fusing the Golgi apparatus into endoplasmic reticulum.	Celecoxib	19-22	cytochrome c oxidase II, mitochondrial	Mus musculus	211-216	
29371019-1	2018	Celecoxib (CLX) is a selective COX-2 inhibitor with anticancer potential in a COX-2 dependent and independent manner.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	78-83	
29371019-1	2018	Celecoxib (CLX) is a selective COX-2 inhibitor with anticancer potential in a COX-2 dependent and independent manner.	Celecoxib	11-14	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36	
29371019-1	2018	Celecoxib (CLX) is a selective COX-2 inhibitor with anticancer potential in a COX-2 dependent and independent manner.	Celecoxib	11-14	cytochrome c oxidase II, mitochondrial	Mus musculus	78-83	
29132705-9	2018	The blockage of COX-2 by celecoxib reversed the benefit of IL-pretreated 17A-MSCs on the serum PGE2 concentration, spleen and kidney Tregs percentages, serum creatinine and BUN levels, renal acute tubular necrosis scores, and serum IL-6, TNF-alpha, IFN-gamma, and IL-10 levels of IRI-pretreated mice with AKI, compared with MSCs.	Celecoxib	25-34	cytochrome c oxidase II, mitochondrial	Mus musculus	16-21	
27711210-6	2016	Administration of celecoxib, a COX-2 inhibitor, suppressed lymphangiogenesis in the granulation tissues and reduced the induction of the pro-lymphangiogenic factors, vascular endothelial growth factor (VEGF) -C and VEGF-D.	Celecoxib	18-27	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36	
27225385-1	2017	As an effective COX-2 inhibitor, celecoxib is widely used in anti-inflammation therapy.	Celecoxib	33-42	cytochrome c oxidase II, mitochondrial	Mus musculus	16-21	
28078603-1	2017	Cyclooxygenase (COX)-2 inhibitors, such as celecoxib, for chronic inflammatory disease are associated with adverse health events, while cis-9, trans-11 (c9t11) conjugated linoleic acid (CLA) is anti-inflammatory without adverse events attributed to pure intake.	Celecoxib	43-52	cytochrome c oxidase II, mitochondrial	Mus musculus	0-22	
28567799-0	2017	COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels.	Celecoxib	27-36	cytochrome c oxidase II, mitochondrial	Mus musculus	0-5	
27216189-6	2016	Importantly, treatment with the COX-2 inhibitor celecoxib significantly inhibited the growth of NF2-null Schwann cells and tumor growth in a mouse model of NF2.	Celecoxib	48-57	cytochrome c oxidase II, mitochondrial	Mus musculus	32-37	
27074576-3	2016	Treatment with celecoxib resulted in G1 cell cycle arrest, induction of apoptosis, inhibition of cellular adhesion and invasion and reduction of expression of hTERT mRNA and COX-2 protein in all of the ovarian cancer cell lines.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Mus musculus	174-179	
27074576-6	2016	In the ovarian tumors from obese and non-obese KpB mice, treatment with celecoxib as compared to control resulted in decreased proliferation, increased apoptosis and reduced COX-2 and MMP9 protein expression, as assessed by immunohistochemistry.	Celecoxib	72-81	cytochrome c oxidase II, mitochondrial	Mus musculus	174-179	
22006370-7	2012	Treatment with celecoxib, a selective COX-2 inhibitor, caused a 45% reduction in mammary PGE(2)  levels, attenuated the influx of mast cells and reduced vascularization in Tg glands.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Mus musculus	38-43	
26856544-11	2016	Macrophage conditioned media (MCM) increased COX-2 and collagen type I expression in vascular smooth muscle cells; the latter was reduced by celecoxib treatment.	Celecoxib	141-150	cytochrome c oxidase II, mitochondrial	Mus musculus	45-50	
25503930-4	2015	It also renders these mice resistant to celecoxib, a selective inhibitor of inducible COX-2 during colon neoplasia.	Celecoxib	40-49	cytochrome c oxidase II, mitochondrial	Mus musculus	86-91	
23992553-1	2014	CONTEXT: Celecoxib is an anti-inflammatory drug, specific inhibitor of COX-2, classified as a BCS class II compound due to its very low aqueous solubility (3 mug/mL) and good permeability.	Celecoxib	9-18	cytochrome c oxidase II, mitochondrial	Mus musculus	71-76	
24945311-4	2014	Celecoxib, a selective COX-2 inhibitor, has been shown to potentially reduce STAT3 phosphorylation.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
24923427-4	2014	METHODS: In the present study, we employed an established mouse model for postmenopausal breast cancer to evaluate the potential mechanisms of the COX-2 inhibitor celecoxib.	Celecoxib	163-172	cytochrome c oxidase II, mitochondrial	Mus musculus	147-152	
24923427-8	2014	Protein expression of ERalpha, COX-2, Cyclin A, and Bcl-xL were reduced in celecoxib-treated tumor samples, whereas only Bcl-xL expression was suppressed in those treated with aspirin.	Celecoxib	75-84	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36	
23770093-1	2013	Celecoxib (Cx), an anti-inflammatory drug designed to inhibit COX2, can affect some ion channels.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	62-66	
23770093-1	2013	Celecoxib (Cx), an anti-inflammatory drug designed to inhibit COX2, can affect some ion channels.	Celecoxib	11-13	cytochrome c oxidase II, mitochondrial	Mus musculus	62-66	
23987495-8	2013	qPCR showed a significant decrease of the mRNA expression of COX-2 in celecoxib group and combined treatment group when compared with control group (P<0.001), but no significant change in NF-KappaB p65.Capecitabine had no significant effects on the mRNA expression of COX-2 and NF-KappaB p65.	Celecoxib	70-79	cytochrome c oxidase II, mitochondrial	Mus musculus	61-66	
23987495-9	2013	Western blotting showed that celecoxib and combined treatment significantly inhibited the protein expression of COX-2 and NF-KappaB p65(P<0.05), but not capecitabine.	Celecoxib	29-38	cytochrome c oxidase II, mitochondrial	Mus musculus	112-117	
23987495-10	2013	CONCLUSION: Celecoxib can enhance the antitumor effect of capecitabine by inhibiting the expressions of COX-2 and NF-KappaB p65 in mice bearing H22 implanted tumor.	Celecoxib	12-21	cytochrome c oxidase II, mitochondrial	Mus musculus	104-109	
23305077-11	2013	The present study substantiates the need to more closely consider selective COX-2 inhibitors such as celecoxib as alternatives to non-selective NSAIDs for therapeutic management in a setting of chronic kidney disease.	Celecoxib	101-110	cytochrome c oxidase II, mitochondrial	Mus musculus	76-81	
23205124-2	2012	Tumor growth and survival time were observed and compared in mice which were treated with a COX-1 inhibitor (SC-560) and a COX-2 inhibitor (celecoxib) every other day for a 21 day period from the day of tumor formation.	Celecoxib	140-149	cytochrome c oxidase II, mitochondrial	Mus musculus	123-128	
26772819-9	2016	Celecoxib treatment was efficient in the regulation of COX2 in the TRAMP mice, mainly in the advanced disease grade.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	55-59	
27159542-8	2016	Interestingly, a single administration of a Cox2 inhibitor (celecoxib) during decidualization restrained Cox2 and IL-15 expression, restored dNK cell numbers, improved fetal growth, and attenuated late gestational hypertension in BPH/5 female mice.	Celecoxib	60-69	cytochrome c oxidase II, mitochondrial	Mus musculus	44-48	
27159542-8	2016	Interestingly, a single administration of a Cox2 inhibitor (celecoxib) during decidualization restrained Cox2 and IL-15 expression, restored dNK cell numbers, improved fetal growth, and attenuated late gestational hypertension in BPH/5 female mice.	Celecoxib	60-69	cytochrome c oxidase II, mitochondrial	Mus musculus	105-109	
25909170-9	2015	Celecoxib, a selective Cox-2 inhibitor, suppressed the HSPA12B-induced increase in lung tumor burden.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
24981602-5	2014	Treating murine macrophage RAW 264.7 cell line with COX-2i celecoxib and EP4A significantly reduced VEGF-A/C/D production in vitro, measured with quantitative PCR and Western blots.	Celecoxib	59-68	cytochrome c oxidase II, mitochondrial	Mus musculus	52-57	
24981602-10	2014	Knocking down COX-2 or EP4 in C3L5 cells or treating cells in vitro with celecoxib or EP4A and treating tumor-bearing mice in vivo with the same drug reduced SLC properties of tumor cells including preferential co-expression of COX-2 and SLC markers ALDH1A, CD44, OCT-3/4, beta-catenin, and SOX-2.	Celecoxib	73-82	cytochrome c oxidase II, mitochondrial	Mus musculus	14-19	
24953691-4	2014	Our study aims to determine the effects of COX-2 inhibitor (celecoxib) on the proliferation and tenocytic differentiation of TDSCs.	Celecoxib	60-69	cytochrome c oxidase II, mitochondrial	Mus musculus	43-48	
24486542-1	2014	BACKGROUND: Previously, we showed that short-term inhibition of beta-catenin expression and reversal of aberrant beta-catenin subcellular localization by the selective COX-2 inhibitor celecoxib is associated with adenoma regression in the C57BL/6J Min/+ mouse.	Celecoxib	184-193	cytochrome c oxidase II, mitochondrial	Mus musculus	168-173	
24900856-7	2014	After intraperitoneal injection, selective uptake of CF3-fluorocoxib A is detected in inflamed mouse paws compared to noninflamed contralateral paws by optical imaging, and uptake is blocked by pretreatment with the COX-2 inhibitor, celecoxib.	Celecoxib	233-242	cytochrome c oxidase II, mitochondrial	Mus musculus	216-221	
24349442-2	2013	We have previously shown that celecoxib inhibits experimental autoimmune encephalomyelitis (EAE) in COX-2-deficient mice, suggestive for a mode of action involving COX2-independent pathways.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Mus musculus	100-105	
24349442-3	2013	In the present study, we tested the effect of a trifluoromethyl analogue of celecoxib (TFM-C) with 205-fold lower COX-2 inhibitory activity in two models of neuroinflammation, i.e. cerebellar organotypic cultures challenged with LPS and the EAE mouse model for multiple sclerosis.	Celecoxib	76-85	cytochrome c oxidase II, mitochondrial	Mus musculus	114-119	
23657858-6	2013	The selective COX-2 inhibitor celecoxib markedly attenuated urinary PGEM excretion and abolished the diuretic response to chronic IL-1beta infusion.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Mus musculus	14-19	
22641101-6	2012	Chronic oral administration of COX-1/COX-2 inhibitor indomethacin, COX-2 inhibitor celecoxib and an EP4 antagonist ONO-AE3-208, but not an EP1 antagonist ONO-8713 at nontoxic doses markedly reduced tumor growth, lymphangiogenesis, angiogenesis, and metastasis to lymph nodes and lungs.	Celecoxib	83-92	cytochrome c oxidase II, mitochondrial	Mus musculus	67-72	
22819976-6	2012	In both tests reversal of FCA induced mechanical hypersensitivity was investigated using the selective COX2 inhibitor celecoxib.	Celecoxib	118-127	cytochrome c oxidase II, mitochondrial	Mus musculus	103-107	
22715053-4	2012	The orexigenic activity of rubiscolin-6 was inhibited by celecoxib, a cyclooxygenase (COX)-2 inhibitor.	Celecoxib	57-66	cytochrome c oxidase II, mitochondrial	Mus musculus	70-92	
21913318-5	2011	Blockade of COX-2 by celecoxib, a COX-2 selective inhibitor, effectively reduced the expression of PGE2 and inhibited differentiation of RAW264.7 cells into tartrate-resistant acid phosphatase-positive (TRAP+) osteoclastic cells.	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Mus musculus	12-17	
22916251-12	2012	The celecoxib-induced downregulation of COX-2 protein and p-5-LOX was also significantly enhanced by GABA under both experimental conditions.	Celecoxib	4-13	cytochrome c oxidase II, mitochondrial	Mus musculus	40-45	
22570721-8	2012	The Gln-ind cells were anchorage-independent, resistant to chemotherapeutic drugs doxorubicin and paclitaxel, and resistant to a high concentration of a COX-2 inhibitor celecoxib.	Celecoxib	169-178	cytochrome c oxidase II, mitochondrial	Mus musculus	153-158	
21913318-5	2011	Blockade of COX-2 by celecoxib, a COX-2 selective inhibitor, effectively reduced the expression of PGE2 and inhibited differentiation of RAW264.7 cells into tartrate-resistant acid phosphatase-positive (TRAP+) osteoclastic cells.	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Mus musculus	34-39	
21268125-5	2011	Topical application of the COX-2 inhibitor, celecoxib, also reduced UVB-induced survivin levels.	Celecoxib	44-53	cytochrome c oxidase II, mitochondrial	Mus musculus	27-32	
21673053-6	2011	Additive antitumor effects with the low CHO diets were observed with the mTOR inhibitor CCI-779 and especially with the COX-2 inhibitor Celebrex, a potent anti-inflammatory drug.	Celecoxib	136-144	cytochrome c oxidase II, mitochondrial	Mus musculus	120-125	
21900596-4	2011	We report a series of novel fluorinated imaging agents, derived from indomethacin or celecoxib that selectively inhibit COX-2.	Celecoxib	85-94	cytochrome c oxidase II, mitochondrial	Mus musculus	120-125	
20630498-8	2010	Celecoxib blocked the stimulatory effect of IL-17A on the expression of COX-2, IL-1alpha, IL-6, IL-8, and IL-11 as well as PGE(2) production, whereas it did not block TNF-alpha expression.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	72-77	
21456064-4	2011	We used a syngeneic pseudo-orthotropic mouse model of prostate cancer to test the efficacy of combining androgen withdrawal with FDA-approved COX-2 inhibitor celecoxib.	Celecoxib	158-167	cytochrome c oxidase II, mitochondrial	Mus musculus	142-147	
21456064-12	2011	CONCLUSION: Celecoxib, a relatively safe COX-2-selective anti-inflammatory drug, significantly increases the efficacy of androgen withdrawal in vivo and warrants further investigation as a complement therapy for advanced prostate cancer.	Celecoxib	12-21	cytochrome c oxidase II, mitochondrial	Mus musculus	41-46	
21589914-8	2011	Treatment of WT mice with the COX-2 inhibitor celecoxib for two weeks decreased the expression of AMPA/KA and NMDAR subunits after KA, as observed in COX-2(-/-) mice.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Mus musculus	30-35	
21589914-8	2011	Treatment of WT mice with the COX-2 inhibitor celecoxib for two weeks decreased the expression of AMPA/KA and NMDAR subunits after KA, as observed in COX-2(-/-) mice.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Mus musculus	150-155	
22140606-8	2011	CONCLUSION: The synergistic anticancer effects of combined low dose gamma-tocotrienol and celecoxib treatment in +SA mammary tumor cells are mediated by COX-2-dependent mechanisms associated with a suppression in PGE(2) levels, as well as, COX-2-independent mechanisms associated with a reduction in ErbB2-4 receptor levels, activation, and subsequent reduction in downstream Akt and NFkappaB mitogenic signaling.	Celecoxib	90-99	cytochrome c oxidase II, mitochondrial	Mus musculus	153-158	
22140606-8	2011	CONCLUSION: The synergistic anticancer effects of combined low dose gamma-tocotrienol and celecoxib treatment in +SA mammary tumor cells are mediated by COX-2-dependent mechanisms associated with a suppression in PGE(2) levels, as well as, COX-2-independent mechanisms associated with a reduction in ErbB2-4 receptor levels, activation, and subsequent reduction in downstream Akt and NFkappaB mitogenic signaling.	Celecoxib	90-99	cytochrome c oxidase II, mitochondrial	Mus musculus	240-245	
21324324-12	2011	LLCC-injected WT mice treated with a COX-2 inhibitor, celecoxib, exhibited similar temporal changes to mPGES1-/-.	Celecoxib	54-63	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42	
21205474-1	2010	OBJECTIVE: To evaluate effects of celecoxib (a selective cox-2 inhibitor)combined with fluvastatin (a HMG-CoA reductase inhibitor) on tumor growth and cell apoptosis in hepatocellular carcinoma xenograft in nude mice.	Celecoxib	34-43	cytochrome c oxidase II, mitochondrial	Mus musculus	57-62	
19159447-10	2009	Addition of celecoxib, a selective COX-2 inhibitor, significantly decreased PGE2 secretion (p < 0.05) versus control, and also significantly decreased FAS activity (p < 0.05).	Celecoxib	12-21	cytochrome c oxidase II, mitochondrial	Mus musculus	35-40	
19800413-5	2009	Central administration of C5a elevated the hypothalamic mRNA expression of COX-2 but not COX-1, and the food intake stimulation of C5a was inhibited by pretreatment with a COX-2 inhibitor, celecoxib, suggesting that C5a activates COX-2 upstream of the PGD(2)-DP(1) system.	Celecoxib	189-198	cytochrome c oxidase II, mitochondrial	Mus musculus	75-80	
19800413-5	2009	Central administration of C5a elevated the hypothalamic mRNA expression of COX-2 but not COX-1, and the food intake stimulation of C5a was inhibited by pretreatment with a COX-2 inhibitor, celecoxib, suggesting that C5a activates COX-2 upstream of the PGD(2)-DP(1) system.	Celecoxib	189-198	cytochrome c oxidase II, mitochondrial	Mus musculus	172-177	
19800413-5	2009	Central administration of C5a elevated the hypothalamic mRNA expression of COX-2 but not COX-1, and the food intake stimulation of C5a was inhibited by pretreatment with a COX-2 inhibitor, celecoxib, suggesting that C5a activates COX-2 upstream of the PGD(2)-DP(1) system.	Celecoxib	189-198	cytochrome c oxidase II, mitochondrial	Mus musculus	172-177	
19387877-6	2009	Compared with control group, a significant redation of angiogenesis and the levels of COX-2, survivin and beta-cantenin protein, and increase of cell apoptosis were detected in tumors in celecoxib group.	Celecoxib	187-196	cytochrome c oxidase II, mitochondrial	Mus musculus	86-91	
19470469-3	2009	In this study, we show that the adenoma prevention activity of the COX-2 inhibitor celecoxib requires the concomitant presence of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) tumor suppressor gene, and that loss of 15-PGDH expression imparts resistance to celecoxib"s anti-tumor effects.	Celecoxib	83-92	cytochrome c oxidase II, mitochondrial	Mus musculus	67-72	
19470469-3	2009	In this study, we show that the adenoma prevention activity of the COX-2 inhibitor celecoxib requires the concomitant presence of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) tumor suppressor gene, and that loss of 15-PGDH expression imparts resistance to celecoxib"s anti-tumor effects.	Celecoxib	263-272	cytochrome c oxidase II, mitochondrial	Mus musculus	67-72	
19218449-5	2009	Administration of celecoxib, a selective COX-2 inhibitor, to tumor-bearing mice decreased xenograft tumor weight and inhibited progression to invasion.	Celecoxib	18-27	cytochrome c oxidase II, mitochondrial	Mus musculus	41-46	
19374162-2	2009	Mice co-treated with CS and celecoxib (a specific COX-2 inhibitor) exhibited a significant decrease in hepatic carcinogen-DNA adduct formation in comparison to the smoke exposed group, however the lungs of the co-treated animals exhibited a significant increase in carcinogen-DNA adduct formation when compared to the control group and smoke exposed group.	Celecoxib	28-37	cytochrome c oxidase II, mitochondrial	Mus musculus	50-55	
20124728-7	2010	Strikingly, uterine deletion of Trp53 increased the incidence of preterm birth, a condition that was corrected by oral administration of the selective COX2 inhibitor celecoxib.	Celecoxib	166-175	cytochrome c oxidase II, mitochondrial	Mus musculus	151-155	
20051370-4	2010	In Ptch1(+/-) mice, genetic deletion of COX1 or COX2 robustly decreased (75%; P < 0.05) microscopic BCC tumor burden, but pharmacologic inhibition with celecoxib reduced microscopic BCCs less efficaciously (35%; P < 0.05).	Celecoxib	155-164	cytochrome c oxidase II, mitochondrial	Mus musculus	48-52	
18178179-3	2008	Pre-treatment with COX-2 inhibitors such as indomethacin, nimesulide, and celecoxib is known to aggravate kainic acid (KA)-induced seizure activity.	Celecoxib	74-83	cytochrome c oxidase II, mitochondrial	Mus musculus	19-24	
19216276-10	2008	CONCLUSION: A specific COX-2 inhibitor NSAID, celecoxib, inhibited growth of osteoblasts on titanium surfaces and the effects were influenced by exposure time and stages of cell growth.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
18572215-6	2008	The concomitant administration of the COX-1 inhibitor, SC-560 (10 mg/kg) and the COX-2 inhibitor, celecoxib (40 mg/kg) 1 h after Jo2 administration, also decreased liver injury 5 h after Jo2 administration.	Celecoxib	98-107	cytochrome c oxidase II, mitochondrial	Mus musculus	81-86	
18454165-6	2008	Also, trypsin response was inhibited by the selective COX-2 inhibitor celecoxib and by the selective kinin B2 (FR173657) and B1 (SSR240612) receptor antagonists.	Celecoxib	70-79	cytochrome c oxidase II, mitochondrial	Mus musculus	54-59	
17950326-4	2008	To clarify the role of COX-2 in atherosclerosis, we conducted a study to test whether the COX-2 inhibitor, celecoxib, prevents the development and progression of the atherosclerotic process.	Celecoxib	107-116	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28	
17950326-4	2008	To clarify the role of COX-2 in atherosclerosis, we conducted a study to test whether the COX-2 inhibitor, celecoxib, prevents the development and progression of the atherosclerotic process.	Celecoxib	107-116	cytochrome c oxidase II, mitochondrial	Mus musculus	90-95	
17950326-12	2008	These findings demonstrate that selective inhibition of the COX-2 enzyme with celecoxib prevented the development of atherosclerotic lesions in the proximal aortas from apo E-/- mice.	Celecoxib	78-87	cytochrome c oxidase II, mitochondrial	Mus musculus	60-65	
18178179-11	2008	An additional COX-2 inhibitor, celecoxib, was administered orally.	Celecoxib	31-40	cytochrome c oxidase II, mitochondrial	Mus musculus	14-19	
15800939-11	2005	However, the COX-2-specific inhibitor, celecoxib, did not reduce Cx43 expression.	Celecoxib	39-48	cytochrome c oxidase II, mitochondrial	Mus musculus	13-18	
17761345-8	2007	These data combine to suggest that celecoxib mainly uses the mitochondrial pathway rather than FADD pathway to trigger apoptosis of COX-2 expressing murine lupus T cells.	Celecoxib	35-44	cytochrome c oxidase II, mitochondrial	Mus musculus	132-137	
17177201-2	2007	We previously demonstrated universal expression of COX-2 in meningiomas and dose-dependent growth inhibition in vitro with celecoxib, a COX-2 inhibitor.	Celecoxib	123-132	cytochrome c oxidase II, mitochondrial	Mus musculus	51-56	
17177201-2	2007	We previously demonstrated universal expression of COX-2 in meningiomas and dose-dependent growth inhibition in vitro with celecoxib, a COX-2 inhibitor.	Celecoxib	123-132	cytochrome c oxidase II, mitochondrial	Mus musculus	136-141	
17177201-13	2007	IOMM-Lee tumors treated with celecoxib showed decreased COX-2 and VEGF expression.	Celecoxib	29-38	cytochrome c oxidase II, mitochondrial	Mus musculus	56-61	
17062693-3	2006	This study investigated whether simultaneously blocking both EGFR and COX-2 pathways with ZD1839 and celecoxib, respectively, would be more effective in inhibiting cell growth and inducing apoptosis than either agent alone.	Celecoxib	101-110	cytochrome c oxidase II, mitochondrial	Mus musculus	70-75	
17049975-3	2006	In this study, we have evaluated the effects of indomethacin (a non-selective COX inhibitor) and celecoxib (a selective COX-2 inhibitor) on the acquisition of morphine-induced conditioned place preference (CPP) in male Swiss mice.	Celecoxib	97-106	cytochrome c oxidase II, mitochondrial	Mus musculus	120-125	
16835249-0	2006	Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Mus musculus	95-100	
16835249-4	2006	Here, we show that a new-generation COX-2 inhibitor, celecoxib, inhibited experimental autoimmune encephalomyelitis (EAE).	Celecoxib	53-62	cytochrome c oxidase II, mitochondrial	Mus musculus	36-41	
16835249-6	2006	Moreover, celecoxib inhibited EAE in COX-2-deficient mice, indicating that celecoxib inhibited EAE in a COX-2-independent manner.	Celecoxib	10-19	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42	
16835249-6	2006	Moreover, celecoxib inhibited EAE in COX-2-deficient mice, indicating that celecoxib inhibited EAE in a COX-2-independent manner.	Celecoxib	75-84	cytochrome c oxidase II, mitochondrial	Mus musculus	104-109	
16505106-10	2006	Celecoxib or piroxicam treatment in athymic mice significantly delayed progression of HT1376 xenografts, which express COX-2, but not UMUC3 xenografts that lack COX-2 expression.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	119-124	
16505106-10	2006	Celecoxib or piroxicam treatment in athymic mice significantly delayed progression of HT1376 xenografts, which express COX-2, but not UMUC3 xenografts that lack COX-2 expression.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	161-166	
16534727-11	2006	At 2 microM, celecoxib inhibited PGE(2) production in the COX-2 WBA by 92 % and in the COX-1 WBA by 50 %.	Celecoxib	13-22	cytochrome c oxidase II, mitochondrial	Mus musculus	58-63	
16216692-0	2005	Discrepancy between effects of milligram and nanogram doses of a COX-2 inhibitor (celecoxib) on morphine state-dependent memory of passive avoidance in mice.	Celecoxib	82-91	cytochrome c oxidase II, mitochondrial	Mus musculus	65-70	
16216692-1	2005	This experiment examined and compared the effects of pre-test administration of a selective COX-2 inhibitor (celecoxib), at the doses in the range of mg/kg and ng/kg on morphine state-dependent learning in step-down passive avoidance task in mice.	Celecoxib	109-118	cytochrome c oxidase II, mitochondrial	Mus musculus	92-97	
16254252-1	2005	Coxibs, such as rofecoxib, celecoxib, and valdecoxib, selectively inhibit cyclooxygenase (COX)-2, the mainly inducible, pro-inflammatory COX isoform.	Celecoxib	27-36	cytochrome c oxidase II, mitochondrial	Mus musculus	74-96	
17306872-6	2007	Acetaminophen, the non-steroidal anti-inflammatory drug indomethacin, and the COX-2-inhibitor celecoxib did not significantly improve pain behavior.	Celecoxib	94-103	cytochrome c oxidase II, mitochondrial	Mus musculus	78-83	
16835249-0	2006	Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Mus musculus	10-15	
16041399-5	2005	Immunohistochemical studies of mouse skin demonstrated that TPA-induced COX-2 expression was significantly inhibited by ethyl caffeate with a superior effect to that of celecoxib, a nonsteroidal anti-inflammatory drug.	Celecoxib	169-178	cytochrome c oxidase II, mitochondrial	Mus musculus	72-77	
15860667-6	2005	Blockade of COX-2 by celecoxib inhibits differentiation of bone marrow-derived monocyte/macrophage precursor cells (BMMs) into tartrate-resistant acid phosphatase-positive (TRAP+) osteoclastic cells.	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Mus musculus	12-17	
15170663-5	2004	The nonselective COX inhibitor indomethacin and the selective COX-2 inhibitor celecoxib reduced tumor growth and metastasis outcome in s.c. LP07 tumor-bearing mice.	Celecoxib	78-87	cytochrome c oxidase II, mitochondrial	Mus musculus	62-67	
15999531-1	2005	Celecoxib (C), a COX-2 enzyme inhibitor, was administered at a 0.1% dose level in the diet of female Swiss Webster CFW outbred mice for life.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	17-22	
15940366-12	2005	Gene expression was increased 5-fold by 4 h, and protein levels reached a maximum after 48 h. Within 1 h, titanium particles also induced COX-2 mRNA and protein levels, whereas both indomethacin and celecoxib blocked the stimulation of RANKL, suggesting a COX-2-mediated event.	Celecoxib	199-208	cytochrome c oxidase II, mitochondrial	Mus musculus	138-143	
15940366-12	2005	Gene expression was increased 5-fold by 4 h, and protein levels reached a maximum after 48 h. Within 1 h, titanium particles also induced COX-2 mRNA and protein levels, whereas both indomethacin and celecoxib blocked the stimulation of RANKL, suggesting a COX-2-mediated event.	Celecoxib	199-208	cytochrome c oxidase II, mitochondrial	Mus musculus	256-261	
15570007-2	2004	Whereas the selective COX-2 inhibitor celecoxib and exisulind, a metabolic product of sulindac, have gained increasing attention as efficacious chemopreventive agents against colon and prostate cancer, not much is known about the underlying molecular targets and mechanisms.	Celecoxib	38-47	cytochrome c oxidase II, mitochondrial	Mus musculus	22-27	
15570007-12	2004	CONCLUSIONS: Overall, the findings from this study clearly show the effectiveness of celecoxib and exisulind in reducing the PIN lesions by modulating a cascade of molecular targets involved in COX-2-dependent and -independent mechanisms.	Celecoxib	85-94	cytochrome c oxidase II, mitochondrial	Mus musculus	194-199	
15451306-7	2004	Postexposure treatment of normal male ICR mice with the selective COX-2 inhibitor celecoxib resulted in significant reductions of 27% (P < 0.05) and 28% (P < 0.01) in ear swelling at intervals of 40 and 60 min between exposure and treatment, respectively.	Celecoxib	82-91	cytochrome c oxidase II, mitochondrial	Mus musculus	66-71	
14767831-5	2004	Inhibition of COX-2 with celecoxib resulted in an earlier onset of CM.	Celecoxib	25-34	cytochrome c oxidase II, mitochondrial	Mus musculus	14-19	
15126378-2	2004	This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model.	Celecoxib	65-74	cytochrome c oxidase II, mitochondrial	Mus musculus	88-93	
15126378-10	2004	Histopathological examination of celecoxib-fed animals showed reduced proliferation, and down-modulation of COX-2 and prostaglandin E2 levels in the dorsolateral prostate and plasma, respectively.	Celecoxib	33-42	cytochrome c oxidase II, mitochondrial	Mus musculus	108-113	
14630706-5	2004	In this study, we show that topical application of SC-560 (a COX-1 selective inhibitor) or celecoxib (COX-2 selective) to TPA-treated wild-type skin caused fivefold increases in the number of basal keratinocytes expressing the early differentiation marker keratin 1 (K1).	Celecoxib	91-100	cytochrome c oxidase II, mitochondrial	Mus musculus	102-107	
12408376-2	2002	Growth and metastasis of these tumors in syngeneic hosts are inhibited by either selective Cox-1 (SC560) or selective Cox-2 (celecoxib) inhibitors.	Celecoxib	125-134	cytochrome c oxidase II, mitochondrial	Mus musculus	118-123	
14690522-7	2004	Surprisingly, both COX-2 (celecoxib; sc-125) or COX-1 (sc-560) selective compounds significantly increased Abeta42 secretion, and either did not alter (sc-560; sc-125) or reduced (celecoxib) Abeta40 levels.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Mus musculus	19-24	
14616542-8	2003	Treatment of these mice with a Cox-2 selective inhibitor, celecoxib, reduced the size of the adenomas.	Celecoxib	58-67	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36	
12902868-4	2003	In this study, we tested the effects of a COX-2 inhibitor (celecoxib) after 50 Gy radiation of MCa-35 tumor and cutaneous tissues of C3H/He mice.	Celecoxib	59-68	cytochrome c oxidase II, mitochondrial	Mus musculus	42-47	
14572603-7	2003	Interestingly, the cyclooxygenase (COX-) 2-selective inhibitor nimesulide (NS) and celecoxib (CXB) showed different responses than those of other inhibitors.	Celecoxib	83-92	cytochrome c oxidase II, mitochondrial	Mus musculus	19-42	
14572603-7	2003	Interestingly, the cyclooxygenase (COX-) 2-selective inhibitor nimesulide (NS) and celecoxib (CXB) showed different responses than those of other inhibitors.	Celecoxib	94-97	cytochrome c oxidase II, mitochondrial	Mus musculus	19-42	
10506108-2	1999	The work described uses the selective COX-2 inhibitor celecoxib to examine the efficacy of COX-2 inhibition in the reduction of UV light-induced skin tumor formation in hairless mice.	Celecoxib	54-63	cytochrome c oxidase II, mitochondrial	Mus musculus	38-43	
11936620-7	2002	COX-2 activity was inhibited with a COX-2 selective drug, celecoxib (Celebrex), and COX-1 was antagonized with SC560.	Celecoxib	58-67	cytochrome c oxidase II, mitochondrial	Mus musculus	0-5	
11936620-7	2002	COX-2 activity was inhibited with a COX-2 selective drug, celecoxib (Celebrex), and COX-1 was antagonized with SC560.	Celecoxib	69-77	cytochrome c oxidase II, mitochondrial	Mus musculus	0-5	
11385116-3	2001	We evaluated the COX-2 inhibitor, Celecoxib, for its tocolytic effects and side-effects on dams and pups using a lipopolysaccharide (LPS)-induced preterm delivery mouse model (preterm delivery rates; 95%).	Celecoxib	34-43	cytochrome c oxidase II, mitochondrial	Mus musculus	17-22	
11085526-2	2000	We have studied the cytotoxic effect of a specific COX-2 inhibitor, celecoxib, against LLC, HCA-7, and HCT-15 cells grown in cell culture and have compared these results with its effect on HCA-7 cells grown as xenografts in nude mice.	Celecoxib	68-77	cytochrome c oxidase II, mitochondrial	Mus musculus	51-56	
11059745-3	2000	In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer.	Celecoxib	51-60	cytochrome c oxidase II, mitochondrial	Mus musculus	35-40	
11016626-3	2000	We used the adenomatous polyposis coli (Apc) mutant Min mouse model to determine whether the selective COX-2 inhibitor celecoxib is effective for adenoma prevention and/or regression, and whether it might be safer than the nonselective NSAID previously shown to be most effective in this model, piroxicam.	Celecoxib	119-128	cytochrome c oxidase II, mitochondrial	Mus musculus	103-108	
12183660-7	2002	The COX2-selective inhibitor, celecoxib, failed to alter the response to IL-1beta 30 min after administration, but low doses antagonized the effects of IL-1beta at 90 to 120 min.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Mus musculus	4-8	
12183660-10	2002	Celecoxib also attenuated the milk intake response observed 2 h after lipopolysaccharide (LPS), and the reductions of food pellet intake and body weight induced by IL-1beta and LPS in the subsequent 24 h, suggesting that the role of COX2 may be more significant biologically than that of COX1.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	233-237	
12150615-2	2002	Celecoxib is a newly developed cyclo-oxygenase (COX)-2 inhibitor with significantly less toxicity.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	31-54	
12086405-9	2002	Dietary administration of indomethacin, piroxicam, or the selective COX-2 inhibitor celecoxib prevented the development of UV-induced skin cancers by up to 85%.	Celecoxib	84-93	cytochrome c oxidase II, mitochondrial	Mus musculus	68-73	
11743745-6	2001	The significantly increased toxicity linked to COX-2 deficiency could be mimicked using the selective COX-2 inhibitory drug, celecoxib, in COX(+/+) mice and was not due to alterations in drug-protein adduct formation, a surrogate for bioactivation and toxicity.	Celecoxib	125-134	cytochrome c oxidase II, mitochondrial	Mus musculus	47-52